CINVANTI injectable emulsion contains the active ingredient, aprepitant. Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, an antiemetic agent, chemically described as 5-[[(2 R ,3 S )-2-[(1 R )-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3 H -1,2,4-triazol-3-one. Its empirical formula is C 23 H 21 F 7 N 4 O 3 , and its structural formula is: Aprepitant is a white to off-white crystalline solid, with a molecular weight of 534.43. It is practically insoluble in water. Aprepitant is sparingly soluble in ethanol and isopropyl acetate and slightly soluble in acetonitrile. CINVANTI (aprepitant) injectable emulsion is a sterile, opaque, off-white to amber liquid in a single-dose vial for intravenous use. Each vial contains 130 mg aprepitant in 18 mL of emulsion. The emulsion also contains the following inactive ingredients: egg lecithin (2602 mg), dehydrated alcohol (513 mg), sodium oleate (87 mg), soybean oil (1734 mg), sucrose (973 mg), and water for injection (12142 mg). Chemical Structure

What kind of drug is aprepitant?

The FDA classifies aprepitant as a substance p/neurokinin-1 receptor antagonist. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.

Can you take aprepitant with other medicines?

It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run aprepitant against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.

What brand names is aprepitant sold under?

We track 2 aprepitant-containing products in the U.S.: Cinvanti and Emend. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.

What forms does aprepitant come in?

Across the brands we track, aprepitant is currently marketed as injectable, emulsion, capsule, powder and kit, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Is there a generic aprepitant?

We do not currently list a generic-labelled aprepitant product. That does not always mean none exists — it means none appears under a generic name in the FDA data we track. Ask your pharmacist.

Has aprepitant been recalled?

The FDA's Enforcement database lists 2 recall records whose product description mentions aprepitant. The most recent: Merck Emend (aprepitant) for oral suspension (Dec 12, 2025). A recall applies to specific lots, not to the drug as a whole — check the record for the affected lot numbers.

Aprepitant: uses, dosing, side effects & brands

Aprepitant is a substance p/neurokinin-1 receptor antagonist sold in the U.S. under 2 brand and generic names. Below: what the FDA label says, every product that contains it, what the pills look like, and its recall record.

By the pharmaranks editorial teamReviewed against the FDA (openFDA label, NDC Directory & Enforcement) sourcesHow we research

Key facts

Drug class: Substance P/Neurokinin-1 Receptor Antagonist
Available as: Injectable · Emulsion · Capsule · Powder · Kit
Sold as: 2 products — Cinvanti and Emend
Prescription?: Prescription only
Generic available?: Not in our catalog
Typical price: about $2007 for a 30-count supply

How aprepitant is dosed

From the FDA label for Cinvanti (application NDA209296). Other aprepitant products — different forms, different strengths — are dosed differently. Follow the label for the one you were prescribed.

Recommended Dosage ( 2.1 ): Administer CINVANTI intravenously as an injection over 2 minutes or an infusion over 30 minutes; complete the injection or infusion approximately 30 minutes prior to chemotherapy. HEC and MEC (Single-Dose Regimen) : The recommended dosage in adults is 130 mg on Day 1. MEC (3-Day Regimen) : The recommended dosage in adults is 100 mg on Day 1. Aprepitant capsules (80 mg) are given orally on Days 2 and 3. CINVANTI is part of a regimen that includes a corticosteroid and a 5-HT 3 antagonist. Preparation : See the full prescribing information for instructions. ( 2.2 ) 2.1 Prevention of Nausea and Vomiting Associated with HEC and MEC The recommended dosages in adults of CINVANTI, dexamethasone, and a 5-HT 3 antagonist for the prevention of nausea and vomiting associated with administration of HEC or MEC are shown in Table 1, Table 2 and Table 3 respectively. Administer CINVANTI intravenously either by injection over a two (2) minute period or by infusion over a thirty (30) minute period on Day 1, completing the injection or infusion approximately 30 minutes prior to chemotherapy. Table 1. Recommended Dosage of CINVANTI for the Prevention of Nausea and Vomiting Associated with HEC (Single-Dose Regimen) Agent Day 1 Day 2 Day 3 Day 4 CINVANTI 130 mg intravenously None None None Dexamethasone Administer dexamethasone 30 minutes prior to chemotherapy treatment…

Aprepitant side effects

The following clinically significant adverse reactions are described elsewhere in the labeling: Hypersensitivity Reactions [see Warnings and Precautions (5.2) ] Most common adverse reactions are: Single-dose fosaprepitant with MEC (≥2%): fatigue, diarrhea, neutropenia, asthenia, anemia, peripheral neuropathy, leukopenia, dyspepsia, urinary tract infection, pain in extremity. ( 6.1 ) 3-day oral aprepitant with MEC (≥1% and greater than standard therapy): fatigue and eructation. ( 6.1 ) Single-dose fosaprepitant with HEC: generally similar to 3-day oral aprepitant. In addition, infusion site reactions (3%) occurred. ( 6.1 ) Single-dose CINVANTI (≥2%): headache and fatigue. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Heron Therapeutics, Inc. at 1-844-437-6611 and www.CINVANTI.com or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice. The safety of CINVANTI was evaluated as a single-dose in healthy subjects and established from adequate and well-controlled studies of intravenous fosaprepitant and/or oral aprepitant [see Clinical Studies (14) ] . Adverse reactions observed in…

Every aprepitant product we track (2)

Same active ingredient — different manufacturer, form, price and FDA recall record. That last one is what our independent score measures.

Aprepitant products
#	Drug	Rating	Type	Form	Generic?	Typical price
1	Cinvanti	Not yet rated	Prescription	Injectable	Generic	$2007	View →
2	Emend	Not yet rated	Prescription	Capsule	Generic	$2007	View →

What aprepitant pills look like

Imprint codes, colour and shape from the FDA’s labelling data. Match the imprint on your pill — or search any imprint.

Aprepitant pill imprints
Imprint	Strength	Colour	Shape	Maker
40mg	40 mg	yellow	capsule	—
80mg	80 mg	white	capsule	—
125mg	125 mg	pink	capsule	—
G;583	40 mg	yellow, white	capsule	—
G;584	80 mg	white, white	capsule	—
G;585	125 mg

Aprepitant recalls

From the FDA Enforcement database. A recall covers specific lots — not the drug as a whole.

Frequently asked questions

What is aprepitant?: CINVANTI injectable emulsion contains the active ingredient, aprepitant. Aprepitant is a substance P/neurokinin 1 (NK 1 ) receptor antagonist, an antiemetic agent, chemically described as 5-[[(2 R ,3 S )-2-[(1 R )-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3 H -1,2,4-triazol-3-one. Its empirical formula is C 23 H 21 F 7 N 4 O 3 , and its structural formula is: Aprepitant is a white to off-white crystalline solid, with a molecular weight of 534.43. It is practically insoluble in water. Aprepitant is sparingly soluble in ethanol and isopropyl acetate and slightly soluble in acetonitrile. CINVANTI (aprepitant) injectable emulsion is a sterile, opaque, off-white to amber liquid in a single-dose vial for intravenous use. Each vial contains 130 mg aprepitant in 18 mL of emulsion. The emulsion also contains the following inactive ingredients: egg lecithin (2602 mg), dehydrated alcohol (513 mg), sodium oleate (87 mg), soybean oil (1734 mg), sucrose (973 mg), and water for injection (12142 mg). Chemical Structure
What kind of drug is aprepitant?: The FDA classifies aprepitant as a substance p/neurokinin-1 receptor antagonist. If you are checking whether it is safe to combine with something else, the class is what matters — two drugs from the same class usually should not be stacked.
Can you take aprepitant with other medicines?: It depends on the medicine. We check it against the FDA labels rather than guessing: our interaction checker searches each drug's own label for the other and quotes what it says, naming the section it came from. Run aprepitant against whatever else you take — and remember that a label not naming a drug is not the same as that combination being safe.
What brand names is aprepitant sold under?: We track 2 aprepitant-containing products in the U.S.: Cinvanti and Emend. They are the same active ingredient; they differ in form, manufacturer, price and FDA recall record.
What forms does aprepitant come in?: Across the brands we track, aprepitant is currently marketed as injectable, emulsion, capsule, powder and kit, per the FDA's National Drug Code Directory. Each form is dosed differently — follow the label for the exact product you were prescribed.

Sources: FDA openFDA drug label, National Drug Code Directory, and Enforcement (recall) database. This page reproduces public FDA data and is not medical advice. Dosing is set by your prescriber.